{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:20:38Z","timestamp":1791836438899,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,12,3]],"date-time":"2017-12-03T00:00:00Z","timestamp":1512259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,12,3]],"date-time":"2017-12-03T00:00:00Z","timestamp":1512259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1111\/bjd.16046","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T10:24:00Z","timestamp":1512469440000},"page":"659-662","source":"Crossref","is-referenced-by-count":34,"title":["Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal"],"prefix":"10.1093","volume":"178","author":[{"given":"A.","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Dermatology; Watford General Hospital; Watford U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Solman","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology; Great Ormond Street Hospital for Children; London WC1N 3JH U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,3]]},"reference":[{"key":"10.1111\/bjd.16046-BIB0001|bjd16046-cit-0001","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaci.2007.11.004","article-title":"Is eczema really on the increase worldwide?","volume":"121","author":"Williams","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16046-BIB0002|bjd16046-cit-0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","article-title":"Management of difficult-to-treat atopic dermatitis","volume":"1","author":"Arkwright","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1111\/bjd.16046-BIB0003|bjd16046-cit-0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0738-081X(02)00368-1","article-title":"The use of corticosteroids and corticosteroid phobia in atopic dermatitis","volume":"21","author":"Charman","year":"2003","journal-title":"Clin Dermatol"},{"key":"10.1111\/bjd.16046-BIB0004|bjd16046-cit-0004","unstructured":"Grindlay DJ Pediatrics. \u2018Petite\u2019 bit of vital information still missing http:\/\/pediatrics.aappublications.org\/content\/135\/4\/597.comments#re-petite-bit-of-vital-information-still-missing"},{"key":"10.1111\/bjd.16046-BIB0005|bjd16046-cit-0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16046-BIB0006|bjd16046-cit-0006","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16046-BIB0007|bjd16046-cit-0007","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1111\/bjd.16046-BIB0008|bjd16046-cit-0008","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/bjd.16046-BIB0009|bjd16046-cit-0009","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.285.15.2000","article-title":"Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials","volume":"285","author":"Devereaux","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/bjd.16046-BIB0010|bjd16046-cit-0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jaad.2006.08.024","article-title":"Evidence-based dermatology: number needed to treat and its relation to other risk measures","volume":"56","author":"Manriquez","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16046-BIB0011|bjd16046-cit-0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1542\/peds.2014-1990","article-title":"Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial","volume":"135","author":"Sigurgeirsson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1111\/bjd.16046-BIB0012|bjd16046-cit-0012","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.jid.2016.05.104","article-title":"How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?","volume":"136","author":"Wilkes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16046-BIB0013|bjd16046-cit-0013","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jid.2017.02.963","article-title":"More atopic dermatitis trials using standard treatments as active comparators please","volume":"137","author":"Wilkes","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16046-BIB0014|bjd16046-cit-0014","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Guidance for industry. Providing clinical evidence of effectiveness for human drug and biological products www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4227B1-02-02-FDA-Appendix1.pdf"},{"key":"10.1111\/bjd.16046-BIB0015|bjd16046-cit-0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaad.2009.06.077","article-title":"Reporting clinical trials: why one plus one does not equal two","volume":"61","author":"Katz","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16046-BIB0016|bjd16046-cit-0016","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/bjd.16046-BIB0017|bjd16046-cit-0017","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16046-BIB0018|bjd16046-cit-0018","unstructured":"Pharmaphorum Pfizer's eczema drug Eucrisa approved https:\/\/pharmaphorum.com\/news\/pfizers-eczema-drug-eucrisa-approved"},{"key":"10.1111\/bjd.16046-BIB0019|bjd16046-cit-0019","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16046-BIB0020|bjd16046-cit-0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaad.2016.06.013","article-title":"Commentary: new drugs for atopic dermatitis may provide clues to basic mechanisms of itch and inflammation","volume":"75","author":"Hanifin","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16046\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:30:12Z","timestamp":1676385012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/3\/659\/6687300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16046","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,3]]}}}